Kevin Bitterman

[Atlas Venture @atlasventure]

Congratulations to the team @MarianaOncology on their acquisition by Novartis for $1B upfront! Having co-founded, seeded, and incubated Mariana with Simon Read as an Atlas EIR, we are excited to follow the advancement of Mariana's drug candidates within @Novartis

[Disc Medicine @DiscMedicine]

In data presented at #EHA2023, Disc announced initial positive results from BEACON, our Phase 2 clinical trial for bitopertin in #EPP. Read more: https://t.co/dokeoBCkxE

[Atlas Venture @atlasventure]

We are so pleased to announce that Jeff Albers has joined Atlas as a Venture Partner! We look forward to working closely with Jeff to build impactful new biotech companies - Welcome Jeff!

[Disc Medicine @DiscMedicine]

Today we announced Disc has completed its merger with Gemini Therapeutics. The combined company, advancing Disc’s pipeline of hematology programs, will commence trading under the ticker symbol $IRON
Read more: https://t.co/uYfpVggVZ6

[Bruce Booth @LifeSciVC]

Takeda Acquires Nimbus’ Tyk2 Autoimmune Program for up to $6B

Congrats to @JebKeiper & the @NimbusTx team!

Here's a blog on the Nimbus' journey - more to come in Chapter 3!

Looking fwd to watching 4858's continued success in Takeda's capable hands

https://t.co/Zapf9IyQva

[Chroma Medicine @chromamedicine]

Chroma welcomes @JeffMarrazzo, founding CEO of Spark Therapeutics to our Board – Jeff’s pioneering contributions to #GeneTherapy and deep experience in #biotech company building will be an asset as we reimagine the future of genomic medicine.

Read more: https://t.co/X6QJ3SGZBr

[Bruce Booth @LifeSciVC]

Another Reach the Beach in the record books! #RTB2022

[Kevin Bitterman @KevinBitterman]

@michael_gilman Real question is what is the ratio of Dead to JGB versions?

[Atlas Venture @atlasventure]

We are thrilled to continue working alongside talented entrepreneurs to build breakthrough biotech startups via our new $450M Atlas Venture Fund XIII

https://t.co/vUbJVL1fh2

[Chroma Medicine @chromamedicine]

We are excited to introduce Chroma Medicine, a genomic medicine company pioneering epigenetic editing to precisely regulate gene expression in disease.

Learn more: https://t.co/LwWknVCh0o

[Atlas Venture @atlasventure]

We are proud to announce Atlas Venture Opportunity Fund II, a $300M fund dedicated to supporting our breakthrough portfolio biotech companies https://t.co/wPiguaecQD

[Project Onramp @ProjectOnramp]

VC firm @atlasventure will welcome their first-ever marketing intern this summer thanks to support from Kristen Margeson!

[Atlas Venture @atlasventure]

We are excited to welcome @SamTruex to the Atlas team today!

https://t.co/tfqmpRZ3c3

[Kevin Bitterman @KevinBitterman]

@JasonPaulRhodes @atlasventure My effort. The stracciatella di bufala was key

[Remix Therapeutics @RemixThera]

Exciting news! Matthew Patterson has joined Remix as Executive Chair! https://t.co/HtMjFG33gk

[Kevin Bitterman @KevinBitterman]

@AlexHarding7 @VedereBio Thanks Alex! You were far more than just along for the ride and appreciate all the work you did to help the company get to this outcome.

[Kevin Bitterman @KevinBitterman]

We couldn’t be more thrilled to see Novartis advance this technology.

[Jay Bradner, M.D. @jaybradner]

Pleased to share that we’re adding @VedereBio’s #optogenetics-based gene therapy tech to our arsenal to bring next-generation gene therapy to an even broader population of patients with blindness

[Atlas Venture @atlasventure]

Congratulations @VedereBio!

[Bruce Booth @LifeSciVC]

"Leave a Ladder Down, Part Deux" - @SamTruex opines on the importance of helping and mentoring others to access career paths and leadership opportunities. @michael_gilman @robperez32 @76viney https://t.co/XnrIaxoJFJ